Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-κB-TNFα-PIK3CA loop

Fig. 5

Cisplatin mediated activation of PI3K/AKT endorsed an anti-apoptotic, dormant state, augmenting CSC in resistant cells. a Flow-chart of SP-differentiation assay, where SP was serially sorted for three successive generation and %SP was determined pre and post TNFα or cisplatin treatment (24 h). b Pie chart showing SP enrichment after TNFα or cisplatin in A2780-CisR cells (MP, top panel). The middle panel depicted the percent increase in SP over generations as described in A and the lower panel depicted %SP after respective condition. The NSP cells did not showed any SP fraction. Data represented as average %SP obtained from three independent biological replicates. c-e. Heat map of relative expression (2-ΔCT) of pluripotent genes OCT4 (c), NANOG (d) and SOX2 (e) in response to cisplatin in MP, SP and NSP of A2780-CisR, TOV21G and SKOV3 cells (n = 3). f&g. Inhibition of PIK3CA activity using wortmannin decreased %SP in MP and 3rd gen SP of control and cisplatin treated A2780-CisR and SKOV3 cells (n = 3). h Comparative expression of the indicated genes in MP, SP and NSP fraction of A2780-CisR cells with and without cisplatin treatment where the least relative expression (2-ΔCT) value was considered be the lowermost color (dark green) of the scale. Data represented as mean of at least three independent replicates, and heat maps were generated with GraphPad prism 7. Also see Additional file 7: Figure S6

Back to article page